Dendritic cell vaccine strategy may improve breast cancer treatment outcomes
Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...
INmune Bio: CORDStrom Is A Game-Changer, As Investors Await Alzheimer's Results
INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...
Dealbreaker on MSN23h
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
AstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.